4/A: Ingevity Corp CEO Corrects Stock Option Grant in Amended SEC Filing
SEC Filing (Form 4/A)
David H. Li, President & CEO of Ingevity Corp, files an amendment to a previous Form 4 to correct the number of employee stock options granted.
Summary
- David H. Li, the President and CEO of Ingevity Corp, filed an amended Form 4 with the SEC on April 17, 2025.
- This amendment corrects a clerical error in the original Form 4 filed on April 9, 2025, which reported an incorrect number of employee stock options granted.
- The corrected filing shows that Li was granted 123,229 employee stock options (right to buy) at a price of $31.73 on April 7, 2025.
- These options will vest ratably in four installments starting on April 7, 2026, and continuing annually until April 7, 2029, and will expire on April 7, 2035.
Sentiment
Score: 7
Explanation: The document is a routine correction of a clerical error in an SEC filing. It doesn't indicate any fundamental issues with the company, but the initial error could raise minor concerns about internal controls. Overall, the sentiment is neutral to slightly positive due to the correction.
Industry Context
This filing is a routine disclosure related to executive compensation and is standard practice for publicly traded companies. It provides transparency regarding the equity-based compensation of key executives.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in publicly traded companies, including those in the specialty chemicals industry like Ingevity.
- Companies such as Celanese, Ashland, and Eastman Chemical also utilize stock options as part of their executive compensation plans.
- The vesting schedules and exercise prices are typically structured to align executive interests with long-term shareholder value creation, similar to industry norms.
Stakeholder Impact
- Shareholders benefit from the increased transparency regarding executive compensation.
- The correction ensures accurate information is available to investors.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date of the stock option grant. |
| 04/09/2025 | Date of the original Form 4 filing with the incorrect information. |
| 04/17/2025 | Date of the amended Form 4 filing. |
| 04/07/2026 | First vesting date for the stock options. |
| 04/07/2027 | Second vesting date for the stock options. |
| 04/07/2028 | Third vesting date for the stock options. |
| 04/07/2029 | Fourth vesting date for the stock options. |
| 04/07/2035 | Expiration date of the stock options. |
Keywords
SEC Form 4, Amendment, Stock Options, Ingevity Corp, David H. Li, NGVT, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.